PRIMARY STUDY

Schizophrenia and depression, two poles of endocannabinoid system deregulation.

Key Findings:  Stimulating the endocannabinoid system, e.g., with CB1R agonists, would ameliorate depressive symptoms, and treatment with antagonists would reduce those of schizophrenia. The possible negative consequences of such exogenous CB1R ligands might be mitigated by the physiology of normal individuals, but preexisting vulnerabilities would displace mood equilibrium to either pole.